KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Non-Current Deffered Revenue (2019 - 2026)

West Pharmaceutical Services has reported Non-Current Deffered Revenue over the past 8 years, most recently at $11.8 million for Q1 2026.

  • Quarterly Non-Current Deffered Revenue rose 3.51% to $11.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $11.8 million through Mar 2026, up 3.51% year-over-year, with the annual reading at $13.5 million for FY2025, 12.34% down from the prior year.
  • Non-Current Deffered Revenue was $11.8 million for Q1 2026 at West Pharmaceutical Services, down from $13.5 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $26.3 million in Q1 2022 and troughed at $11.4 million in Q1 2025.
  • The 5-year median for Non-Current Deffered Revenue is $17.9 million (2023), against an average of $17.0 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: rose 16.89% in 2022 and later tumbled 38.71% in 2025.
  • Tracing WST's Non-Current Deffered Revenue over 5 years: stood at $19.1 million in 2022, then decreased by 2.62% to $18.6 million in 2023, then dropped by 17.2% to $15.4 million in 2024, then decreased by 12.34% to $13.5 million in 2025, then decreased by 12.59% to $11.8 million in 2026.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $11.8 million, $13.5 million, and $13.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.